WILMINGTON, Mass.--(BUSINESS WIRE)--Mar. 29, 2021-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million, subject to customary...
WILMINGTON, Mass.--(BUSINESS WIRE)--Mar. 29, 2021-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously...
Read More
Cognate BioServices, Inc., the premier commercial-ready, global CDMO in the Cell and Gene Therapy industry, announced today its plans to expand cell and gene therapy...
Read More
L7 Informatics announced that it has partnered with Cognate BioServices, Inc., the premier commercial-ready CDMO in the Cell & Gene Therapy industry, to deploy L7|ESP...
Read More
MEMPHIS, Tennessee, November 2, 2020 /PRNewswire/ -- Cognate BioServices, Inc., the premier commercial-ready CDMO in the Cell & Gene Therapy industry, announced today the...
Read More
Join Cognate's CEO, J. Kelly Ganjei, as he speaks at the upcoming Morgan Stanley Global Healthcare Conference - Thursday, September 17 at 2:45pm EDT. ...
Read More
Ernst & Young LLP (EY US) today announced that J. Kelly Ganjei, CEO of Cognate BioServices, Inc. was named an Entrepreneur Of The Year® 2020 Southeast Award finalist. Now in...
Read More
